IDEAYA Biosciences, Inc. - Common Stock (IDYA)
Frequently Asked Questions About IDEAYA Biosciences, Inc. - Common Stock (IDYA)
Does IDEAYA have any programs for patient access or assistance?
Yes, IDEAYA is committed to ensuring patient access to its clinical trials and potential therapies. The company has programs designed to assist eligible patients, including outreach initiatives that inform patients about ongoing studies and potential access to investigational treatments through compassionate use or expanded access protocols.
How can investors access information about IDEAYA?
Investors can access information about IDEAYA through the company's website, where they can find financial reports, press releases, and updates on clinical trials. Additionally, IDEAYA participates in investor conferences and provides quarterly earnings calls, allowing investors to stay informed about the latest developments and financial performance.
How does IDEAYA fund its research and development?
IDEAYA funds its research and development through a combination of equity financing, partnership collaborations, and grants. The company leverages its public market status to access capital while also seeking collaborative agreements with larger pharmaceutical companies that can provide financial support and resources for shared development projects.
How does IDEAYA mitigate risks in drug development?
IDEAYA mitigates risks in drug development by employing a rigorous scientific approach that includes comprehensive preclinical studies and biomarker analysis. The company also collaborates with experienced partners and continuously monitors regulatory standards and market dynamics to ensure a strategic pipeline of product candidates that align with patient needs.
What are IDEAYA's key competitive advantages?
IDEAYA's key competitive advantages include its targeted approach to precision medicine, a strong pipeline of therapeutics backed by robust biomarker studies, and its capable management team with extensive experience in biotechnology and pharmaceutical industries. Additionally, the company’s focus on unmet medical needs in oncology positions it favorably in the competitive landscape.
What are the main therapeutic areas IDEAYA focuses on?
IDEAYA focuses primarily on oncology, developing therapies for various forms of cancer. The company aims to create targeted treatments that can provide better outcomes for patients based on their genetic profiles and biomarkers, particularly in solid tumors and genetically defined cancer populations.
What does IDEAYA Biosciences, Inc. do?
IDEAYA Biosciences, Inc. is a biotechnology company focused on the development of precision medicines for the treatment of cancer and other diseases. The company utilizes a biomarker-driven approach to identify and target specific patient populations with genetic profiles that may benefit from its therapeutic candidates. Its research spans various modalities, including small molecules and genomically targeted therapies, aiming to address significant unmet needs in oncology.
What future goals does IDEAYA have?
Looking ahead, IDEAYA aims to advance its current drug candidates through clinical trials, expand its pipeline with new targets and therapies, and enhance its collaborations in precision medicine. The company is focused on delivering breakthroughs in cancer treatment and increasing the therapeutic options available to patients with specific genetic profiles.
What is IDEAYA's lead product candidate?
IDEAYA's lead product candidate is a small molecule inhibitor targeting the protein known as MAT2A (methionine adenosyltransferase 2A). This candidate is designed to disrupt cancer metabolism in tumors with specific genetic alterations, and is being investigated in clinical trials for its efficacy and safety in treating cancers associated with these biomarkers.
What is the intellectual property strategy of IDEAYA?
IDEAYA fosters a strong intellectual property strategy to protect its innovative technologies and product candidates. This includes filing patents for its proprietary discoveries, innovative drug formulations, and unique treatment protocols, ensuring exclusive rights that could strengthen its competitive position and market potential.
What is the stock symbol for IDEAYA Biosciences?
The stock symbol for IDEAYA Biosciences is IDYA, and it trades on the Nasdaq stock exchange. The company went public through an initial public offering (IPO) in 2020, allowing investors to gain access to its innovative research and growth potential in the precision medicine space.
What is the vision of IDEAYA Biosciences?
The vision of IDEAYA Biosciences is to be a leader in precision medicine, transforming the treatment of cancer through innovative therapies that are tailored to the genetic makeup of individual patients. The company is committed to improving patient outcomes by developing targeted treatments and prioritizing the discovery of novel biomarkers.
What recent milestones has IDEAYA achieved?
Recently, IDEAYA has achieved several important milestones, including advancements in its clinical trial programs, successful fund raising efforts, and the announcement of key collaborations that enhance its drug development capabilities. The company remains focused on progressing its lead therapeutic candidates through clinical development stages and generating promising clinical data.
What role does technology play in IDEAYA's R&D strategy?
Technology plays a critical role in IDEAYA's research and development strategy by enabling the identification of biomarkers and the design of targeted therapeutics. Advanced computational tools, genomic analyses, and other cutting-edge technologies are employed to facilitate drug discovery and development, allowing for more efficient and effective solutions in oncology.
What types of clinical trials is IDEAYA conducting?
IDEAYA is conducting various clinical trials that include early-phase studies (Phase 1 and Phase 2) for its lead and support product candidates. These trials are designed to assess the safety, efficacy, and optimal dosing of its investigational therapies in patients with specific genetic biomarkers related to different cancer types.
What values drive IDEAYA as a company?
The values that drive IDEAYA include innovation, integrity, collaboration, and a commitment to patient-centric solutions. The company prioritizes scientific excellence and ethical considerations throughout its drug development process and fosters a culture of teamwork and transparency both within the organization and with external partners.
When was IDEAYA Biosciences founded?
IDEAYA Biosciences was founded in 2014. The company was established to advance the field of precision medicine by leveraging its expertise in drug development, along with collaborations with academic institutions and industry partners, to discover and develop innovative treatments for cancer patients.
Where is IDEAYA Biosciences headquartered?
IDEAYA Biosciences is headquartered in South San Francisco, California. This location puts the company at the heart of one of the leading biotechnology hubs, providing access to key resources, talent, and collaborations within the life sciences industry.
Who are IDEAYA's collaborators?
IDEAYA has established collaborations with various academic and industry partners, including prominent research institutions and pharmaceutical companies. These collaborations enhance IDEAYA's research capabilities, help advance its drug development programs, and provide access to complementary technologies and expertise in the field.
What is the current price of IDEAYA Biosciences, Inc. - Common Stock?
The current price of IDEAYA Biosciences, Inc. - Common Stock is 16.35
When was IDEAYA Biosciences, Inc. - Common Stock last traded?
The last trade of IDEAYA Biosciences, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of IDEAYA Biosciences, Inc. - Common Stock?
The market capitalization of IDEAYA Biosciences, Inc. - Common Stock is 791.18M
How many shares of IDEAYA Biosciences, Inc. - Common Stock are outstanding?
IDEAYA Biosciences, Inc. - Common Stock has 48.39M shares outstanding.